Business
AstraZeneca COVID-19 vaccine trial data results in revised efficacy rate
The Oxford-AstraZeneca PLC (LON: AZN) COVID-19 vaccine has travelled a bumpy road through its development and rollout. Marred with accusations of the vaccine causing blood clots, regulatory and government pressures have weighed on the drug developer and its acceptance.
According to the latest press release from AstraZeneca, the company has revised the vaccine’s efficacy from 79% to 76%, following further analysis with an additional 49 symptomatic COVID-19 cases.
Details of the COVID-19 vaccine findings
After scrutiny from the US National Institute of Allergy and Infectious Diseases for purportedly out-of-date data in the original…
-
General21 hours agoWallabies vs Italy rugby union Test live updates — blog, scores and stats from Udine
-
General20 hours agoHow the dismissal of Gough Whitlam’s Labor government in 1975 was sealed by the Senate
-
Noosa News13 hours agoPhotographer Nadia Shevtsova remembered by family in touching tribute after deadly crash at Gold Coast
-
Business21 hours ago3 US stocks that could make you rich